Halozyme Therapeutics (HALO) CEO exercises options and sells stock under 10b5-1 plan

Filing Impact

(Very High)

Filing Sentiment

(Very Negative)

Form Type

Rhea-AI Filing Summary

Halozyme Therapeutics, Inc. President and CEO Helen Torley, who is also a director, reported a series of option exercises and related stock sales in early February 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on March 21, 2025.

On February 3–5, 2026, she exercised company stock options at an exercise price of $12.07 per share and sold the resulting common shares in multiple transactions at weighted average prices generally in the mid-to-high $70s per share, as detailed in the price ranges disclosed for each trade.

Following these transactions, she directly held 708,719 shares of Halozyme common stock and 201,923 options to purchase common stock, with the options originally granted on February 22, 2017 and exercisable over a four-year vesting schedule.

Insider Trade Summary

Net Seller: 50,000 shares ($3,853,503)

Net Sell 13 txns

Insider Torley Helen

Role PRESIDENT AND CEO

Sold 50,000 shs ($3.85M)

Type	Security	Shares	Price	Value
Exercise	Option to Purchase Common Stock	10,000	$12.07	$121K
Exercise	Common Stock	10,000	$12.07	$121K
Sale	Common Stock	5,376	$78.379	$421K
Sale	Common Stock	4,624	$78.936	$365K
Exercise	Option to Purchase Common Stock	20,000	$12.07	$241K
Exercise	Common Stock	20,000	$12.07	$241K
Sale	Common Stock	9,900	$76.936	$762K
Sale	Common Stock	10,100	$77.54	$783K
Exercise	Option to Purchase Common Stock	20,000	$12.07	$241K
Exercise	Common Stock	20,000	$12.07	$241K
Sale	Common Stock	2,551	$74.879	$191K
Sale	Common Stock	9,659	$75.944	$734K
Sale	Common Stock	7,790	$76.734	$598K

Holdings After Transaction: Option to Purchase Common Stock — 201,923 shares (Direct); Common Stock — 718,719 shares (Direct)

Footnotes (1)

The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027. Represents a weighted average sales price per share. The shares were sold at prices ranging from $74.450 to $75.442. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $75.470 to $76.460. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $76.490 to $77.030. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $76.275 to $77.260. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $77.290 to $77.990. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $77.640 to $78.637. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $78.643 to $79.292. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 22, 2017.

Form 4 Insider Transactions: What Each Field Means →

02/05/2026 - 07:38 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Torley Helen

(Last)

(First)

(Middle)

C/O HALOZYME THERAPEUTICS, INC.

12390 EL CAMINO REAL

(Street)

SAN DIEGO

92130

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	PRESIDENT AND CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/03/2026		M⁽¹⁾		20,000	A	$12.07	728,719	D
Common Stock	02/03/2026		S⁽¹⁾		2,551	D	$74.879⁽²⁾	726,168	D
Common Stock	02/03/2026		S⁽¹⁾		9,659	D	$75.944⁽³⁾	716,509	D
Common Stock	02/03/2026		S⁽¹⁾		7,790	D	$76.734⁽⁴⁾	708,719	D
Common Stock	02/04/2026		M⁽¹⁾		20,000	A	$12.07	728,719	D
Common Stock	02/04/2026		S⁽¹⁾		9,900	D	$76.936⁽⁵⁾	718,819	D
Common Stock	02/04/2026		S⁽¹⁾		10,100	D	$77.54⁽⁶⁾	708,719	D
Common Stock	02/05/2026		M⁽¹⁾		10,000	A	$12.07	718,719	D
Common Stock	02/05/2026		S⁽¹⁾		5,376	D	$78.379⁽⁷⁾	713,343	D
Common Stock	02/05/2026		S⁽¹⁾		4,624	D	$78.936⁽⁸⁾	708,719	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Option to Purchase Common Stock	$12.07	02/03/2026		M⁽¹⁾			20,000	⁽⁹⁾	02/22/2027	Common Stock	20,000	$12.07	231,923	D
Option to Purchase Common Stock	$12.07	02/04/2026		M⁽¹⁾			20,000	⁽⁹⁾	02/22/2027	Common Stock	20,000	$12.07	211,923	D
Option to Purchase Common Stock	$12.07	02/05/2026		M⁽¹⁾			10,000	⁽⁹⁾	02/22/2027	Common Stock	10,000	$12.07	201,923	D

Explanation of Responses:

1. The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027.

2. Represents a weighted average sales price per share. The shares were sold at prices ranging from $74.450 to $75.442. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

3. Represents a weighted average sales price per share. The shares were sold at prices ranging from $75.470 to $76.460. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

4. Represents a weighted average sales price per share. The shares were sold at prices ranging from $76.490 to $77.030. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

5. Represents a weighted average sales price per share. The shares were sold at prices ranging from $76.275 to $77.260. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

6. Represents a weighted average sales price per share. The shares were sold at prices ranging from $77.290 to $77.990. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

7. Represents a weighted average sales price per share. The shares were sold at prices ranging from $77.640 to $78.637. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

8. Represents a weighted average sales price per share. The shares were sold at prices ranging from $78.643 to $79.292. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

9. Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 22, 2017.

Remarks:

	/s/ James R. Oehler, Attorney-in-Fact	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider activity did HALO CEO Helen Torley report on this Form 4?

Helen Torley reported exercising stock options and selling Halozyme common shares in several transactions on February 3–5, 2026. The trades involved options with a $12.07 exercise price and subsequent open-market sales at weighted average prices generally in the mid-to-high $70s per share.

Were Helen Torley’s HALO stock trades made under a Rule 10b5-1 plan?

Yes. The filing states the option exercises and sales were made under a written trading plan adopted on March 21, 2025, in accordance with Rule 10b5-1. Such plans pre-schedule trades, helping separate routine diversification from discretionary, event-driven insider trading decisions.

What options did Helen Torley exercise in this Halozyme Form 4?

She exercised options to purchase Halozyme common stock at an exercise price of $12.07 per share in multiple transactions on February 3, 4, and 5, 2026. The options were originally granted on February 22, 2017 and vest over a four-year period from that grant date.

At what prices did the HALO CEO sell Halozyme common stock?

The sales used weighted average prices per trade, with reported averages such as $74.879, $75.944, $76.734, $76.936, $77.54, $78.379 and $78.936. Each footnote discloses that individual sale prices within those trades fell within narrow ranges around the reported weighted averages.

How many Halozyme shares does Helen Torley hold after these transactions?

After the reported February 2026 trades, she directly held 708,719 shares of Halozyme common stock. She also beneficially owned 201,923 options to purchase common stock, reflecting remaining derivative holdings after exercising a portion of her previously granted, vested stock options.

What is the vesting and term of the HALO options referenced in this Form 4?

The options were granted on February 22, 2017, with a four-year vesting schedule: 25% after 12 months, then 1/48th of the option shares each month. They have a ten-year term, expiring in February 2027, and were exercised at a fixed $12.07 per-share exercise price.